[
  {
    "ts": null,
    "headline": "The Cost Of Being Totally Out Of Sync With An AI-Driven Speculative Market",
    "summary": "The Cost Of Being Totally Out Of Sync With An AI-Driven Speculative Market",
    "url": "https://finnhub.io/api/news?id=6e62a2e456da400f7c738565e4933f0a8ac8834daa15a3cebda04eca0df0606b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771971900,
      "headline": "The Cost Of Being Totally Out Of Sync With An AI-Driven Speculative Market",
      "id": 139203669,
      "image": "",
      "related": "TMO",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=6e62a2e456da400f7c738565e4933f0a8ac8834daa15a3cebda04eca0df0606b"
    }
  },
  {
    "ts": null,
    "headline": "Thermo Fisher Scientific Inc. (TMO) Carries a Mid-Single Digit Organic Growth Forecast",
    "summary": "Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the 10 best life sciences stocks to buy according to hedge funds. On January 30, Daniel Arias of Stifel Nicolaus maintained a Buy rating on Thermo Fisher Scientific Inc. (NYSE:TMO), with a $700 price target. The analyst reflected on the company’s strong finish to 2025, highlighting that […]",
    "url": "https://finnhub.io/api/news?id=c94858298f6a7f5725ef8f57a8314beacc7a2549bc786a80d5c092fefa1c5db4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771961421,
      "headline": "Thermo Fisher Scientific Inc. (TMO) Carries a Mid-Single Digit Organic Growth Forecast",
      "id": 139200971,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the 10 best life sciences stocks to buy according to hedge funds. On January 30, Daniel Arias of Stifel Nicolaus maintained a Buy rating on Thermo Fisher Scientific Inc. (NYSE:TMO), with a $700 price target. The analyst reflected on the company’s strong finish to 2025, highlighting that […]",
      "url": "https://finnhub.io/api/news?id=c94858298f6a7f5725ef8f57a8314beacc7a2549bc786a80d5c092fefa1c5db4"
    }
  },
  {
    "ts": null,
    "headline": "Henry Schein Q4 Earnings Call Highlights",
    "summary": "Henry Schein (NASDAQ:HSIC) reported fourth-quarter 2025 results on Feb. 24, 2026, highlighting what management described as its “highest sales growth in 15 quarters,” alongside progress on its 2025–2027 BOLD+1 strategic plan and an update to its leadership transition. Leadership transition and stra",
    "url": "https://finnhub.io/api/news?id=85ec7de1b54b262d330ccc8c833c88c12d6647d464f8026c6fa13830f6c0bc36",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771951646,
      "headline": "Henry Schein Q4 Earnings Call Highlights",
      "id": 139198892,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "Henry Schein (NASDAQ:HSIC) reported fourth-quarter 2025 results on Feb. 24, 2026, highlighting what management described as its “highest sales growth in 15 quarters,” alongside progress on its 2025–2027 BOLD+1 strategic plan and an update to its leadership transition. Leadership transition and stra",
      "url": "https://finnhub.io/api/news?id=85ec7de1b54b262d330ccc8c833c88c12d6647d464f8026c6fa13830f6c0bc36"
    }
  },
  {
    "ts": null,
    "headline": "Cancer Diagnostics Market Competitive Landscape Report 2025: Key Players Analysis, Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and Future Forecasts to 2033",
    "summary": "The Cancer Diagnostics Market is set to grow from USD 197.7 billion in 2025 to USD 345.57 billion by 2033, driven by a 7.23% CAGR. Factors like rising cancer incidence, technological advancements in diagnostics, and the importance of early detection are pivotal for this expansion. The market is also fueled by a demand for personalized medicine and enhanced imaging services. Leading companies like Illumina, Abbott Laboratories, and Thermo Fisher Scientific aid this growth through innovations in g",
    "url": "https://finnhub.io/api/news?id=0f090f23c2fd4e1af43df66d3e63e30751355fc39b2da2f76f0122c1c6506a7d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771949760,
      "headline": "Cancer Diagnostics Market Competitive Landscape Report 2025: Key Players Analysis, Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and Future Forecasts to 2033",
      "id": 139198889,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "The Cancer Diagnostics Market is set to grow from USD 197.7 billion in 2025 to USD 345.57 billion by 2033, driven by a 7.23% CAGR. Factors like rising cancer incidence, technological advancements in diagnostics, and the importance of early detection are pivotal for this expansion. The market is also fueled by a demand for personalized medicine and enhanced imaging services. Leading companies like Illumina, Abbott Laboratories, and Thermo Fisher Scientific aid this growth through innovations in g",
      "url": "https://finnhub.io/api/news?id=0f090f23c2fd4e1af43df66d3e63e30751355fc39b2da2f76f0122c1c6506a7d"
    }
  },
  {
    "ts": null,
    "headline": "Lung Cancer Diagnostics Competitive Landscape Report 2025: Key Players Analysis, Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and Future Forecasts to 2033",
    "summary": "The Lung Cancer Diagnostics Market is set to expand from US$ 21.74 billion in 2025 to US$ 38.00 billion by 2033, growing at a CAGR of 7.23%. Major growth drivers include increased public access facilities, rise in ambulance services, and higher prevalence of cardiac disorders. Advances in lung cancer detection techniques like chest X-rays, CT scans, and MRIs cater to the demand for early and accurate diagnoses, crucial for effective treatment. Market leaders such as Illumina, Abbott Laboratories",
    "url": "https://finnhub.io/api/news?id=dfcfe20862fbdc93928d26dd3528ca7b65844b162c317dc98fc0d793a68b573d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771949460,
      "headline": "Lung Cancer Diagnostics Competitive Landscape Report 2025: Key Players Analysis, Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and Future Forecasts to 2033",
      "id": 139198890,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "The Lung Cancer Diagnostics Market is set to expand from US$ 21.74 billion in 2025 to US$ 38.00 billion by 2033, growing at a CAGR of 7.23%. Major growth drivers include increased public access facilities, rise in ambulance services, and higher prevalence of cardiac disorders. Advances in lung cancer detection techniques like chest X-rays, CT scans, and MRIs cater to the demand for early and accurate diagnoses, crucial for effective treatment. Market leaders such as Illumina, Abbott Laboratories",
      "url": "https://finnhub.io/api/news?id=dfcfe20862fbdc93928d26dd3528ca7b65844b162c317dc98fc0d793a68b573d"
    }
  },
  {
    "ts": null,
    "headline": "Thermo Fisher’s Datavant Data Tie-Up Could Be A Game Changer For Thermo Fisher Scientific (TMO)",
    "summary": "Earlier in February 2026, Thermo Fisher Scientific’s PPD clinical research business announced a data collaboration with Datavant to securely connect de-identified real-world patient data across more than 350 data partners and 80,000 U.S. hospitals and clinics into its clinical research, registry and Evidera solutions. This partnership deepens Thermo Fisher’s push into data- and AI-enabled real-world evidence, enhancing its role as an integrated partner for pharma and biotech customers. We’ll...",
    "url": "https://finnhub.io/api/news?id=797ec6b923d880994a76f3993db7b4625be9029010c6267f858e338c0baf0ea4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771945765,
      "headline": "Thermo Fisher’s Datavant Data Tie-Up Could Be A Game Changer For Thermo Fisher Scientific (TMO)",
      "id": 139197406,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "Earlier in February 2026, Thermo Fisher Scientific’s PPD clinical research business announced a data collaboration with Datavant to securely connect de-identified real-world patient data across more than 350 data partners and 80,000 U.S. hospitals and clinics into its clinical research, registry and Evidera solutions. This partnership deepens Thermo Fisher’s push into data- and AI-enabled real-world evidence, enhancing its role as an integrated partner for pharma and biotech customers. We’ll...",
      "url": "https://finnhub.io/api/news?id=797ec6b923d880994a76f3993db7b4625be9029010c6267f858e338c0baf0ea4"
    }
  },
  {
    "ts": null,
    "headline": "Harbor Long-Term Growers ETF Q4 2025 Portfolio Performance",
    "summary": "Harbor Long-Term Growers ETF Q4 2025 Portfolio Performance",
    "url": "https://finnhub.io/api/news?id=e339e6785c75aebdc08978bddfa3e9a7547b48dbf07d8f308e18c69c2e0f1bed",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771945440,
      "headline": "Harbor Long-Term Growers ETF Q4 2025 Portfolio Performance",
      "id": 139201097,
      "image": "",
      "related": "TMO",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=e339e6785c75aebdc08978bddfa3e9a7547b48dbf07d8f308e18c69c2e0f1bed"
    }
  },
  {
    "ts": null,
    "headline": "Thermo Fisher Scientific to Present at Raymond James Annual Institutional Investors Conference",
    "summary": "WALTHAM, Mass., February 24, 2026--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the Raymond James Institutional Investors Conference on Tuesday, March 3, 2026, at 9:15 a.m. (ET).",
    "url": "https://finnhub.io/api/news?id=1ef5189d80de0eff438c192becc5eb908a4b42ff5e169c8530b403824f0d1181",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771938000,
      "headline": "Thermo Fisher Scientific to Present at Raymond James Annual Institutional Investors Conference",
      "id": 139194498,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "WALTHAM, Mass., February 24, 2026--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the Raymond James Institutional Investors Conference on Tuesday, March 3, 2026, at 9:15 a.m. (ET).",
      "url": "https://finnhub.io/api/news?id=1ef5189d80de0eff438c192becc5eb908a4b42ff5e169c8530b403824f0d1181"
    }
  },
  {
    "ts": null,
    "headline": "Next Generation Sequencing Market Competitive Landscape Report 2025 Featuring Top Players - Thermo Fisher Scientific, Pacific Biosciences, Illumina, Roche",
    "summary": "The Next-Generation Sequencing (NGS) market is set to surge from $14.79 billion in 2025 to $56.25 billion by 2033, with a robust CAGR of 18.17%. Key drivers include advancements in sequencing technologies, applications in genomics and personalized medicine, and increased biotech investments. NGS revolutionizes DNA sequencing by rapidly reading millions of genome fragments, enhancing research in genomics, cancer, and infectious diseases. Major players like Illumina, Thermo Fisher Scientific, and",
    "url": "https://finnhub.io/api/news?id=ce959205bcf3fca783ea272ae8e195fe8dfa4aeb1fbc6d993bf19816f989d55f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771932840,
      "headline": "Next Generation Sequencing Market Competitive Landscape Report 2025 Featuring Top Players - Thermo Fisher Scientific, Pacific Biosciences, Illumina, Roche",
      "id": 139193299,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "The Next-Generation Sequencing (NGS) market is set to surge from $14.79 billion in 2025 to $56.25 billion by 2033, with a robust CAGR of 18.17%. Key drivers include advancements in sequencing technologies, applications in genomics and personalized medicine, and increased biotech investments. NGS revolutionizes DNA sequencing by rapidly reading millions of genome fragments, enhancing research in genomics, cancer, and infectious diseases. Major players like Illumina, Thermo Fisher Scientific, and",
      "url": "https://finnhub.io/api/news?id=ce959205bcf3fca783ea272ae8e195fe8dfa4aeb1fbc6d993bf19816f989d55f"
    }
  },
  {
    "ts": null,
    "headline": "Assisted Reproductive Technology Market Competitive Analysis Report 2025: Key Players Analysis, Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and Forecasts to 2033",
    "summary": "The global Assisted Reproductive Technology (ART) market is poised for significant growth, with a value of USD 29.59 billion in 2025, projected to reach USD 49.30 billion by 2033 at a 6.59% CAGR. Key drivers include rising infertility rates, technological advances, and increased awareness of fertility treatments. ART encompasses IVF, ICSI, cryopreservation, and more to aid in conception. Major players like Thermo Fisher, CooperSurgical, and Merck KGaA are propelling innovations and market reach.",
    "url": "https://finnhub.io/api/news?id=bfe41530e62e0b900925a51aa0270f256a4a60f2419b9d070a52a333058123f2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771929480,
      "headline": "Assisted Reproductive Technology Market Competitive Analysis Report 2025: Key Players Analysis, Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and Forecasts to 2033",
      "id": 139193300,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "The global Assisted Reproductive Technology (ART) market is poised for significant growth, with a value of USD 29.59 billion in 2025, projected to reach USD 49.30 billion by 2033 at a 6.59% CAGR. Key drivers include rising infertility rates, technological advances, and increased awareness of fertility treatments. ART encompasses IVF, ICSI, cryopreservation, and more to aid in conception. Major players like Thermo Fisher, CooperSurgical, and Merck KGaA are propelling innovations and market reach.",
      "url": "https://finnhub.io/api/news?id=bfe41530e62e0b900925a51aa0270f256a4a60f2419b9d070a52a333058123f2"
    }
  },
  {
    "ts": null,
    "headline": "Thermo Fisher Scientific (TMO) Valuation Check As Datavant Data Partnership Draws Fresh Investor Interest",
    "summary": "Thermo Fisher Scientific (TMO) is in focus after announcing a data collaboration with Datavant that connects real world data to clinical research, an effort aimed at supporting stronger evidence generation for pharma and biotech clients. See our latest analysis for Thermo Fisher Scientific. Thermo Fisher Scientific’s recent data partnerships and the planned Clario acquisition come as the stock shows mixed momentum, with a 7 day share price return of 2.30% but a 30 day share price return...",
    "url": "https://finnhub.io/api/news?id=bf12f32f64da820a3d9c4d09a3383181c37f258aa26895549c71720aa0d651c6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771927825,
      "headline": "Thermo Fisher Scientific (TMO) Valuation Check As Datavant Data Partnership Draws Fresh Investor Interest",
      "id": 139193301,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "Thermo Fisher Scientific (TMO) is in focus after announcing a data collaboration with Datavant that connects real world data to clinical research, an effort aimed at supporting stronger evidence generation for pharma and biotech clients. See our latest analysis for Thermo Fisher Scientific. Thermo Fisher Scientific’s recent data partnerships and the planned Clario acquisition come as the stock shows mixed momentum, with a 7 day share price return of 2.30% but a 30 day share price return...",
      "url": "https://finnhub.io/api/news?id=bf12f32f64da820a3d9c4d09a3383181c37f258aa26895549c71720aa0d651c6"
    }
  },
  {
    "ts": null,
    "headline": "Nanorobotics Market Competitive Landscape Report 2025: Key Players Analysis, Company Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and Future Forecasts to 2033",
    "summary": "The nano robotics market, valued at USD 9.36 billion in 2025, is projected to surge to USD 22.16 billion by 2033, with a CAGR of 11.37%. Key growth drivers include rising personalized healthcare applications, investments enhancing research efficiency, and leveraging less invasive cancer therapies. Nano robotics—devices engineered at the nanoscale (1-100 nm)—enables groundbreaking applications in drug delivery and diagnostics. Industry leaders like Oxford Instruments, Thermo Fisher Scientific, an",
    "url": "https://finnhub.io/api/news?id=7759a2d18130c30e6bb9bafc3146155abbafc41ba0d427a08fdb7ecd6630da10",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771923960,
      "headline": "Nanorobotics Market Competitive Landscape Report 2025: Key Players Analysis, Company Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and Future Forecasts to 2033",
      "id": 139192464,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "The nano robotics market, valued at USD 9.36 billion in 2025, is projected to surge to USD 22.16 billion by 2033, with a CAGR of 11.37%. Key growth drivers include rising personalized healthcare applications, investments enhancing research efficiency, and leveraging less invasive cancer therapies. Nano robotics—devices engineered at the nanoscale (1-100 nm)—enables groundbreaking applications in drug delivery and diagnostics. Industry leaders like Oxford Instruments, Thermo Fisher Scientific, an",
      "url": "https://finnhub.io/api/news?id=7759a2d18130c30e6bb9bafc3146155abbafc41ba0d427a08fdb7ecd6630da10"
    }
  },
  {
    "ts": null,
    "headline": "How Is The Market Feeling About Thermo Fisher Scientific Inc?",
    "summary": "",
    "url": "https://finnhub.io/api/news?id=6ed1d47cfff5295fdea23e5db7cf206a39f6273d58420d162798c51ee37e2514",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771923639,
      "headline": "How Is The Market Feeling About Thermo Fisher Scientific Inc?",
      "id": 139196354,
      "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/movers_1.jpg?width=2048&height=1536",
      "related": "TMO",
      "source": "Benzinga",
      "summary": " ",
      "url": "https://finnhub.io/api/news?id=6ed1d47cfff5295fdea23e5db7cf206a39f6273d58420d162798c51ee37e2514"
    }
  },
  {
    "ts": null,
    "headline": "Is It Time To Revisit Thermo Fisher Scientific (TMO) After Recent Share Price Weakness?",
    "summary": "If you are wondering whether Thermo Fisher Scientific's current share price reflects its underlying worth, this article will walk you through what the numbers are really saying about value. The stock last closed at US$516.44, with recent returns of 2.3% over 7 days, a 17.5% decline over 30 days, a 12.8% decline year to date, and a 3.2% decline over 1 year, while the 5 year return sits at 13.9%. Recent news coverage has focused on Thermo Fisher Scientific's role in life sciences tools,...",
    "url": "https://finnhub.io/api/news?id=0b59290176e24212bf28412ebc5adc8df03d11490f086e6cb4b73a0e8be6bbba",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771920540,
      "headline": "Is It Time To Revisit Thermo Fisher Scientific (TMO) After Recent Share Price Weakness?",
      "id": 139192465,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "If you are wondering whether Thermo Fisher Scientific's current share price reflects its underlying worth, this article will walk you through what the numbers are really saying about value. The stock last closed at US$516.44, with recent returns of 2.3% over 7 days, a 17.5% decline over 30 days, a 12.8% decline year to date, and a 3.2% decline over 1 year, while the 5 year return sits at 13.9%. Recent news coverage has focused on Thermo Fisher Scientific's role in life sciences tools,...",
      "url": "https://finnhub.io/api/news?id=0b59290176e24212bf28412ebc5adc8df03d11490f086e6cb4b73a0e8be6bbba"
    }
  },
  {
    "ts": null,
    "headline": "Russia's war on Ukraine puts women off having children — and that could spell economic disaster",
    "summary": "Four years of war have discouraged Ukrainian and Russian women from having children, and that could impact their economies in the future.",
    "url": "https://finnhub.io/api/news?id=53795300e06e0d4454e6b04b451c0e619690754126ab2762ed8dab8647314a9d",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771895025,
      "headline": "Russia's war on Ukraine puts women off having children — and that could spell economic disaster ",
      "id": 139198069,
      "image": "https://image.cnbcfm.com/api/v1/image/108268945-1771917055711-gettyimages-1583281302-uk_20230807_ukr61.jpeg?v=1771917103&w=1920&h=1080",
      "related": "TMO",
      "source": "CNBC",
      "summary": "Four years of war have discouraged Ukrainian and Russian women from having children, and that could impact their economies in the future.",
      "url": "https://finnhub.io/api/news?id=53795300e06e0d4454e6b04b451c0e619690754126ab2762ed8dab8647314a9d"
    }
  }
]